Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression

References

• Moreno I, Martin G, Bolufer P, et al. Incidence and prognostic value of FLT3 internal tandem duplication and D835 mutations in acute myeloid leukemia. Haematologica. 2003;88:19–24.
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19:1345–1349.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Luger SM. Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia? Curr Opin Hematol. 2014;21:72–78.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Levis M. How I treat FLT3-mutated AML. Blood. 2016 [cited 2016 Nov 12]; [22 p.]. DOI:10.1182/blood-2016-09-693648
   Web of Science ®Google Scholar
• Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction, high-dose C consolidation, and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18-60 with FLT3 mutations: an international prospective randomized P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]). Blood (Annual Meeting Abstract). 2015;126:6.
   Google Scholar
• Röllig C, Serve H, Hüttmann A, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2015;16:1691–1699.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Gojo I, Karp JE, et al. Prospective study of peri-transplant use of sorafenib as remission maintenance for FLT3-ITD patients undergoing allogeneic transplantation. Blood (Annual Meeting Abstract). 2015;126:3164.
   Google Scholar
• Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 2011;117:3294–3301.
   PubMed Web of Science ®Google Scholar
• Blanpain C, Mohrin M, Sotiropoulou PA, et al. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell. 2011;8:16–29.
   PubMed Web of Science ®Google Scholar
• Pikor L, Thu K, Vucic E, et al. The detection and implication of genome instability in cancer. Cancer Metastasis Rev. 2013;32:341–352.
   PubMed Web of Science ®Google Scholar
• Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214–218.
   PubMed Web of Science ®Google Scholar
• Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 2008;270:1–9.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120:2254–2264.
   PubMed Web of Science ®Google Scholar
• Skorski T. Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state. Leuk Lymphoma. 2011;52:23–29.
   PubMed Web of Science ®Google Scholar
• Skorski T. Genomic instability: the cause and effect of BCR/ABL tyrosine kinase. Curr Hematol Malig Rep. 2007;2:69–74.
   PubMedGoogle Scholar
• Slupianek A, Nowicki MO, Koptyra M, et al. BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells. DNA Repair (Amst). 2006;5:243–250.
   PubMed Web of Science ®Google Scholar
• Nowicki MO, Falinski R, Koptyra M, et al. BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood. 2004;104:3746–3753.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Dasgupta Y, Ren SY, et al. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia. Blood. 2011;118:1062–1068.
   PubMed Web of Science ®Google Scholar
• Deutsch E, Jarrousse S, Buet D, et al. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. Blood. 2003;101:4583–4588.
   PubMed Web of Science ®Google Scholar
• Cramer K, Nieborowska-Skorska M, Koptyra M, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 2008;68:6884–6888.
   PubMed Web of Science ®Google Scholar
• Valeri A, Alonso-Ferrero ME, Rio P, et al. Bcr/Abl interferes with the Fanconi anemia/BRCA pathway: implications in the chromosomal instability of chronic myeloid leukemia cells. PLoS One. 2010;5:e15525.
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. ASH Education Program Book. 2009;2009:461–476.
   Google Scholar
• Koptyra M, Falinski R, Nowicki MO, et al. BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108:319–327.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Koh BD, Patel AG, et al. Poly (ADP-ribose) polymerase inhibitor hypersensitivity in aggressive myeloproliferative neoplasms. Clin Cancer Res. 2016;22:3894–3902.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–397.
   PubMed Web of Science ®Google Scholar
• Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood. 2008;112:1402–1412.
   PubMed Web of Science ®Google Scholar
• Nakatake M, Monte-Mor B, Debili N, et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene. 2012;31:1323–1333.
   PubMed Web of Science ®Google Scholar
• Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol. 2002;22:4189–4201.
   PubMed Web of Science ®Google Scholar
• Fan J, Li L, Small D, et al. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood. 2010;116:5298–5305.
   PubMed Web of Science ®Google Scholar
• Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. Blood. 2013;122:1293–1304.
   PubMed Web of Science ®Google Scholar
• Tobin LA, Robert C, Rapoport AP, et al. Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias. Oncogene. 2013;32:1784–1793.
   PubMed Web of Science ®Google Scholar
• Pratz KW, Rudek MA, Gojo I, et al. Poly (ADP-Ribose) polymerase inhibitor hypersensitivity in aggressive myeloproliferative neoplasms. Clin Cancer Res. 2016;22:3894–3902.
   PubMed Web of Science ®Google Scholar
• Gourdin TS, Zou Y, Ning Y, et al. High frequency of rare structural chromosome abnormalities at relapse of cytogenetically normal acute myeloid leukemia with FLT3 internal tandem duplication. Can Genet. 2014;207:467–473.
   PubMed Web of Science ®Google Scholar
• McCormick SR, McCormick MJ, Grutkoski PS, et al. FLT3 mutations at diagnosis and relapse in acute myeloid leukemia: cytogenetic and pathologic correlations, including cuplike blast morphology. Arch Pathol Lab Med. 2010;134:1143–1151.
   PubMed Web of Science ®Google Scholar
• Rebechi M, Hand W, Smith BD, et al. Structural chromosomal changes are common manifestation of FLT3 ITD relapse and presence of chromosomal progression is independent of normal karyotype at diagnosis. Blood (Annual Meeting Abstract). 2016;128:2868.
   Google Scholar
• Poletto M, Lirussi L, Wilson DM, 3rd, et al. Nucleophosmin modulates stability, activity, and nucleolar accumulation of base excision repair proteins. Mol Biol Cell. 2014;25:1641–1652.
   PubMed Web of Science ®Google Scholar
• Zhou F, Shen Q, Claret FX. Novel roles of reactive oxygen species in the pathogenesis of acute myeloid leukemia. J Leukoc Biol. 2013;94:423–429.
   PubMed Web of Science ®Google Scholar
• Hole PS, Darley RL, Tonks A. Do reactive oxygen species play a role in myeloid leukemias? Blood. 2011;117:5816–5826.
   PubMed Web of Science ®Google Scholar
• Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000;275:24273–24278.
   PubMed Web of Science ®Google Scholar
• Landry WD, Woolley JF, Cotter TG. Imatinib and Nilotinib inhibit Bcr-Abl-induced ROS through targeted degradation of the NADPH oxidase subunit p22phox. Leuk Res. 2013;37:183–189.
   PubMed Web of Science ®Google Scholar
• Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005;105:1717–1723.
   PubMed Web of Science ®Google Scholar
• Sallmyr A, Fan J, Datta K, et al. Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML. Blood. 2008;111:3173–3182.
   PubMed Web of Science ®Google Scholar
• Stanicka J, Russell EG, Woolley JF, et al. NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells. J Biol Chem. 2015;290:9348–9361.
   PubMed Web of Science ®Google Scholar
• O’Hagan HM, Wang W, Sen S, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell. 2011;20:606–619.
   PubMed Web of Science ®Google Scholar
• Valavanidis A, Vlachogianni T, Fiotakis K, et al. Pulmonary oxidative stress, inflammation and cancer: respirable particulate matter, fibrous dusts and ozone as major causes of lung carcinogenesis through reactive oxygen species mechanisms. IJERPH. 2013;10:3886–3907.
   Web of Science ®Google Scholar
• Godfrey R, Arora D, Bauer R, et al. Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/PTPRJ. Blood. 2012;119:4499–4511.
   PubMed Web of Science ®Google Scholar
• Arora D, Stopp S, Bohmer SA, et al. Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. J Biol Chem. 2011;286:10918–10929.
   PubMed Web of Science ®Google Scholar
• Burma S, Chen BP, Murphy M, et al. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem. 2001;276:42462–42467.
   PubMed Web of Science ®Google Scholar
• Seedhouse CH, Hunter HM, Lloyd-Lewis B, et al. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia. 2006;20:2130–2136.
   PubMed Web of Science ®Google Scholar
• Mackarehtschian K, Hardin JD, Moore KA, et al. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3:147–161.
   PubMed Web of Science ®Google Scholar
• McKenna HJ, Stocking KL, Miller RE, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. 2000;95:3489–3497.
   PubMed Web of Science ®Google Scholar
• Li L, Piloto O, Nguyen HB, et al. Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood. 2008;111:3849–3858.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang L, Fan J, et al. Defective nonhomologous end joining blocks B-cell development in FLT3/ITD mice. Blood. 2011;117:3131–3139.
   PubMed Web of Science ®Google Scholar
• Jankovic M, Nussenzweig A, Nussenzweig MC. Antigen receptor diversification and chromosome translocations. Nat Immunol. 2007;8:801–808.
   PubMed Web of Science ®Google Scholar
• Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem. 2010;79:181–211.
   PubMed Web of Science ®Google Scholar
• Allen C, Halbrook J, Nickoloff JA. Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res. 2003;1:913–920.
   PubMed Web of Science ®Google Scholar
• Simsek D, Jasin M. Alternative end-joining is suppressed by the canonical NHEJ component Xrcc4/ligase IV during chromosomal translocation formation. Nat Struct Mol Biol. 2010;17:410–416.
   PubMed Web of Science ®Google Scholar
• Darling DC, Mufti GJ. Internal tandem duplication mutation of FLT3 (FLT3/ITD) induces increased homologous recombination DNA repair activity, drug resistance and sister chromatid exchanges in acute myeloid leukaemia (AML). Blood. 2013;122:1244.
   Web of Science ®Google Scholar
• Li L, Bailey E, Greenblatt S, et al. Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice. Blood. 2011;118:4935–4945.
   PubMed Web of Science ®Google Scholar
• Stirewalt DL, Pogosova-Agadjanyan EL, Tsuchiya K, et al. Copy-neutral loss of heterozygosity is prevalent and a late event in the pathogenesis of FLT3/ITD AML. Blood Cancer J. 2014;4:e208.
   PubMed Web of Science ®Google Scholar
• Stark JM, Pierce AJ, Oh J, et al. Genetic steps of mammalian homologous repair with distinct mutagenic consequences. Mol Cell Biol. 2004;24:9305–9316.
   PubMed Web of Science ®Google Scholar
• Fernandes MS, Reddy MM, Gonneville JR, et al. BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood. 2009;114:1813–1819.
   PubMed Web of Science ®Google Scholar
• Canitrot Y, Falinski R, Louat T, et al. p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood. 2003;102:2632–2637.
   PubMed Web of Science ®Google Scholar
• Stoklosa T, Poplawski T, Koptyra M, et al. BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations. Cancer Res. 2008;68:2576–2580.
   PubMed Web of Science ®Google Scholar
• Nomdedeu JF, Perea G, Estivill C, et al. Microsatellite instability is not an uncommon finding in adult de novo acute myeloid leukemia. Ann Hematol. 2005;84:368–375.
   PubMed Web of Science ®Google Scholar
• Das-Gupta EP, Seedhouse CH, Russell NH. Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia. Br J Haematol. 2001;114:307–312.
   PubMed Web of Science ®Google Scholar
• Gaymes TJ, Mohamedali AM, Patterson M, et al. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies. Haematologica. 2013;98:1397–1406.
   PubMed Web of Science ®Google Scholar
• Brown P, Levis M, Shurtleff S, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood. 2005;105:812–820.
   PubMed Web of Science ®Google Scholar
• Lin EI, Tseng LH, Gocke CD, et al. Mutational profiling of colorectal cancers with microsatellite instability. Oncotarget. 2015;6:42334–42344.
   PubMed Web of Science ®Google Scholar
• De Lange T. Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol. 2005;70:197–204.
   PubMedGoogle Scholar
• Aalbers AM, Calado RT, Young NS, et al. Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia. Leukemia. 2013;27:1786–1789.
   PubMed Web of Science ®Google Scholar
• Watts JM, Dumitriu B, Hilden P, et al. Telomere length is associated with specific mutations and mutation classes in patients with acute myeloid leukemia. Blood. 2014;124:2280.
   PubMed Web of Science ®Google Scholar
• Swiggers SJ, Kuijpers MA, de Cort MJ, et al. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Gene Chromosomes Cancer. 2006;45:247–256.
   PubMed Web of Science ®Google Scholar
• Hartmann U, Brummendorf TH, Balabanov S, et al. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica. 2005;90:307–316.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Bartocci C, Ouzounov I, et al. A two-step mechanism for TRF2-mediated chromosome-end protection. Nature. 2013;494:502–505.
   PubMed Web of Science ®Google Scholar
• Garg M, Nagata Y, Kanojia D, et al. Profiling of somatic mutations in acute myeloid leukemia with FLT3-ITD at diagnosis and relapse. Blood. 2015;126:2491–2501.
   PubMed Web of Science ®Google Scholar
• Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069–1075.
   PubMed Web of Science ®Google Scholar
• Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506–510.
   PubMed Web of Science ®Google Scholar
• Pratz K, Levis M. Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma. 2008;49:852–863.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Barrett R, Liu Q, et al. FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Update. 2009;12:81–89.
   PubMed Web of Science ®Google Scholar
• Wander SA, Levis MJ, Fathi AT. The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond. Ther Adv Hematol. 2014;5:65–77.
   PubMedGoogle Scholar
• Galanis A, Ma H, Rajkhowa T, et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014;123:94–100.
   PubMed Web of Science ®Google Scholar
• Zimmerman EI, Turner DC, Buaboonnam J, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013;122:3607–15.
   Web of Science ®Google Scholar
• Mori M, Kaneko N, Ueno Y, etet al. ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML). ASCO Meeting Abstracts. 2014;32:7070.
   Google Scholar
• Ueno Y, Kaneko N, Saito R, et al. ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia (AML). ASCO Meeting Abstracts. 2014;32:7071.
   Google Scholar
• Zhang W, Gao C, Konopleva M, et al. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies. Clin Cancer Res. 2014;20:2363–2374.
   PubMed Web of Science ®Google Scholar
• Naidoo J, Drilon A. KRAS-mutant lung cancers in the era of targeted therapy. Adv Exp Med Biol. 2016;893:155–178.
   PubMedGoogle Scholar
• Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–1876.
   PubMed Web of Science ®Google Scholar
• Meyn RE, Munshi A, Haymach JV, et al. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol. 2009;92:316–322.
   PubMed Web of Science ®Google Scholar
• Kurosu T, Nagao T, Wu N, et al. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis. PLoS One. 2013;8:e79478.
   PubMed Web of Science ®Google Scholar
• Chang L, Graham PH, Hao J, et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 2014;5:e1437.
   PubMed Web of Science ®Google Scholar
• Cardnell RJ, Feng Y, Diao L, et al. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013;19:6322–6328.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick DS, Bustos DJ, Dogan T, et al. Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Proc Natl Acad Sci USA. 2013;110:19426–19431.
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010;10:293–301.
   PubMed Web of Science ®Google Scholar
• Gojo I, Beumer JH, Pratz KW, et al. A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res. 2016. DOI:10.1158/1078-0432.CCR-16-0984
   Web of Science ®Google Scholar
• Wray J, Williamson EA, Singh SB, et al. PARP1 is required for chromosomal translocations. Blood. 2013;121:4359–4365.
   PubMed Web of Science ®Google Scholar
• Yaghmour G, Pandey M, Ireland C, et al. Role of genomic instability in immunotherapy with checkpoint inhibitors. Anticancer Res. 2016;36:4033–4038.
   PubMed Web of Science ®Google Scholar
• Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016;28:22–27.
   PubMed Web of Science ®Google Scholar